Coya Net Income From Continuing Ops from 2010 to 2026
| COYA Stock | 4.71 0.03 0.63% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -13.4 M | Current Value -14.1 M | Quarterly Volatility 4 M |
Check Coya Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Coya Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.4 K, Interest Expense of 2.9 M or Selling General Administrative of 5.4 M, as well as many indicators such as Price To Sales Ratio of 14.85, Dividend Yield of 0.0 or PTB Ratio of 1.85. Coya financial statements analysis is a perfect complement when working with Coya Therapeutics Valuation or Volatility modules.
Coya | Net Income From Continuing Ops | Build AI portfolio with Coya Stock |
Analyzing Coya Therapeutics's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Coya Therapeutics's current valuation and future prospects.
Latest Coya Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Coya Therapeutics Common over the last few years. It is Coya Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Coya Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Coya Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (7,390,800) | |
| Coefficient Of Variation | (54.53) | |
| Mean Deviation | 3,528,011 | |
| Median | (4,891,792) | |
| Standard Deviation | 4,029,900 | |
| Sample Variance | 16.2T | |
| Range | 10M | |
| R-Value | (0.80) | |
| Mean Square Error | 6.3T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | (636,189) | |
| Total Sum of Squares | 259.8T |
Coya Net Income From Continuing Ops History
About Coya Therapeutics Financial Statements
Coya Therapeutics stakeholders use historical fundamental indicators, such as Coya Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Coya Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Coya Therapeutics' assets and liabilities are reflected in the revenues and expenses on Coya Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Coya Therapeutics Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.4 M | -14.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Coya Therapeutics Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Coya Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Coya Therapeutics Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Coya Therapeutics Common Stock:Check out the analysis of Coya Therapeutics Correlation against competitors. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics. Projected growth potential of Coya fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Coya Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.11) | Revenue Per Share | Quarterly Revenue Growth (0.95) | Return On Assets | Return On Equity |
The market value of Coya Therapeutics Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics' market value can be influenced by many factors that don't directly affect Coya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Coya Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Coya Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Coya Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.